Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Bernard J Smilde, Clemens Stockklausner, Richard Keen, Andrew Whittaker, Alex N Bullock, Annette von Delft, Natasja M van Schoor, Paul B Yu, E Marelise W Eekhoff

Journal title: BMC Musculoskeletal Disorders

Journal number: 23

Journal publisher: BioMed Central

Published year: 2022

Published pages: 519

DOI identifier: 10.1186/s12891-022-05471-x

ISSN: 1471-2474